SINOPHARM(CNCM LTD)(SH:600511) Shang Hai Zheng Quan Bao·2025-08-20 19:44Group 1 - The company held its eighth board meeting on August 19, 2025, where all seven directors attended, including four independent directors [3][4] - The board approved the 2025 semi-annual report and the special report on the use of raised funds, with unanimous votes [4][6] - The company has implemented a management system for raised funds, ensuring compliance with relevant regulations [17][28] Group 2 - The company raised a total of RMB 1,029,999,754.80, with a net amount received of RMB 1,018,217,601.99 after deducting issuance costs [12][14] - As of June 30, 2025, the company used RMB 8.5 billion of idle raised funds to temporarily supplement working capital [21] - The company has completed the "Information System Construction Project" and has no remaining expenditures related to this project [15][21] Group 3 - The company announced the resignation of Vice President Ye Tong due to retirement, effective immediately upon delivery of the resignation letter [30][31] - The company confirmed that Ye Tong's departure will not affect its normal operations [31]